Introduction
Materials and methods
Search strategy
Inclusion criteria
Exclusion criteria
Data collection and analysis
Methodological quality
Description
RCTs | Population | Etiology | Treatment | Add-on therapy | Outcome |
---|---|---|---|---|---|
Painter et al. [23] | N = 59; term and preterm | N = 49 HIE N = 6 CNS infections N = 3 cryptogenic | N = 30 PHB N = 29 PHE Dose: N/A | N = 15 PHE as 2nd line AED N = 13 PHB as 2nd line AED | PHB’s efficacy: 43%. PHE’s efficacy: 45%. When combined, efficacy raised to 57–62%. |
Boylan et al. [24] | N = 22; term and preterm. | N = 13 HIE N = 3 IVH N = 1 BFNE N = 2 IUGR N = 1 premature N = 1 myopathy N = 1 AVM | N = 22 PHB (20–40 mg/kg) | N = 3 MDZ N = 5 LID N = 3 CLZ | 50% response to PHB. 2/5 responded to LID as 2nd line treatment. No response to CLZ and MDZ. |
Pressler et al. [25] | N = 14; term. | HIE | BMT (0.05–03 mg/kg) + PHB (10 mg/kg) | N = 8 MDZ N = 5 PHE N = 2 LID N = 4 PHB | 5/14 had seizure cessation on BMT + PHB. 3/14 had hearing loss. |
Falsaperla et al. [26] | N = 30; term. | N = 23 HIE N = 3 stroke N = 4 CNS infection | PHB (20 mg/kg load, maintenance 5 mg/kg) OR LEV (load dose 20 mg/kg, maintenance 20–40 mg/kg) | / | LEV’s administration related to a significantly positive HNNE score. There was no significant improvement in the HNNE score after one month in the neonates treated with PHB. |
Prospective studies | Population | Etiology | Treatment | Add-on therapy | Outcome |
---|---|---|---|---|---|
Ramantani et al. [27] | N = 38; term and preterm. | N = 9 HIE N = 16 IVH N = 13 sepsis | N = 38 LEV (10–30 mg/kg) | N = 11 PHB as 2nd line | LEV’s efficacy: 79%; 27/30 (90%) remained seizure free at 4 weeks. |
Sharpe et al. [28] | N = 18; term. | N = 8 HIE N = 2 IVH N = 1 birth trauma N = 2 stroke N = 1 brain malformation N = 4 N/A | PHB (20 mg/kg) | LEV (20-40 mg/kg) | LEV’s efficacy: 42%. 5 of the responders were among the 12 subjects who received the higher dose of LEV. |
Furwentsches et al. [29] | N = 6; term and preterm | N = 1 HIE N = 1 IVH N = 3 brain malformation N = 1 N/A | N = 4 oral LEV (10–50 mg/kg) N = 2 PHB (10 mg/kg) | N = 2 LEV | All 6 patients treated with oral LEV became seizure free within 6 days. After 3 months, five out of six patients were seizure free under monotherapy with LEV. |
Falsaperla et al. [30] | N = 16; late preterm and term. | N = 5 MAS N = 8 RDS N = 3 APD | LEV (10–40 mg/kg) | / | LEV’s efficacy: 100%.Seizure freedom reached from 24 h to 15 days. EEGs at three months resulted normal. |
Boylan et al. [31] | N = 17 | N = 7 HIE N = 1 RDS N = 1 IUGR N = 3 sepsis N = 3 prematurity N = 1 NAS N = 1 kernicterus | N = 15 PHB (20–30 mg/kg) | N = 2 PHE (20 mg/kg) | Full response to PHB in 6/17 (35%). Partial response to PHB in 6/17 (35%). No response in 2/17 (12%). |
Low et al. [32] | N = 19 term or near term | N = 10 HIE N = 6 stroke N = 1 CNS infection N = 1 BFNE N = 1 N/A | PHB 10–40 mg/kg i.v. | PHE or MDZ as 2nd line (dose: N/A) | PHB abolished seizurs in 13/19 patients within 1 h. Only 3 patients showed permanent reduction. Loading dose of 20 mg/kg was more effective than 10 mg/kg. |
Van der Broek et al. [33] | N = 53 term newborns | HIE | PHB 20–40 mg/kg | MDZ c.i. 0.05–0.1 mg/kg/h | The observed responsiveness of MDZ add-on therapy after PHB monotherapy was low (23%) compared to PHB monotherapy’s effectiveness (66%). |
Hellstrom- Westas et al. [34] | N = 24 both term and preterm | N = 15 HIE N = 6 IVH N = 2 HIE N = 1 hypoglicemia | N = 24 PHB (10–15 mg/kg) | N = 21 DZP as 2nd line (0.5–2 mg/kg) N = 24 LID as 3rd line (1.6–2.2 mg/kg) | LID’s introduction conducted to seizure cessation in 15/24 patients. 2 of them developed bradycardia and acidosis. |
Maytal et al. [35] | N = 7 | N = 4 HIE N = 2 IVH N = 1 CNS infections | N = 7 PHB (20–40 mg/kg) | N = 7 LRZ (0.05 mg/kg i.v.) | After PHB’s failure, 6/7 patients had complete cessation of seizures within 3 min. 4/6 remained seizure-free on follow-up. No side-effects were reported. |
Glass et al. [36] | N = 92 | N = 30 HIE N = 25 IVH | N = N/A PHB (20 mg/kg) N = N/A LEV (dose: N/A) N = N/A PHE (dose: N/A) | N/A | 64% had seizures that persisted after loading doses of PHB, 58% after LEV and 100% after PHE. . |
Glass et al. [37] | N = 543 term and preterm | N = 284 HIE N = 142 stroke N = 108 IVH | N = 508 PHB N = 21 LEV N = 5 PHE (doses: N/A) | N/A | 354/543 (66%) neonates had incomplete response to the initial loading dose of AED. Incomplete response was similar for PHB (66%), LEV (67%), PHE (80%). |
Retrospective studies | Population | Etiology | Treatment | Add-on therapy | Outcome |
---|---|---|---|---|---|
Abend et al. [38] | N = 23 late preterm and term | N = 8 HIE N = 4 genetic N = 3 malformative N = 3 infections N = 2 cryptogenic N = 2 stroke N = 1 tumor | N = 18 PHB (dose: N/A) N = 1 PHE (dose: N/A) N = 4 LEV (10–20 mg/kg) | N = 13 LEV as 2nd line (dose: N/A) N = 5 LEV as 3rd line | Seizure cessation in 7/23 (30%); seizure reduction (> 50%) in 1/23. |
Khan et al. [39] | N = 22 term | N = 12 HIE N = 2 IVH N = 2 CNS infections N = 6 various | N = 16 PHB (dose: N/A) N = 3 LEV (dose: N/A) | N = 19 received LEV as 2nd (N = 16), 3rd (N = 2) or 4th (N = 1) line | 7 of 22 patients (32%) achieved complete cessation of seizures after administration of the loading dose, 14 (64%) achieved cessation of seizures by 24 h, 19 (86%) by 48 h, and all 22 (100%) by 72 h |
Khan et al. [40] | N = 12 preterm | N = 5 HIE N = 3 IVH N = 3 N/A N = 1 HSV encephalitis | N = 9 PHB (dose: N/A) N = 3 LID (dose: N/A) | N = 12 LEV (dose: N/A) | 4 patients (36%) reached seizure cessation after the loading dose, 9 (82%) by 24 h, 10 (91%) by 48 h, and 10 subjects (91%) by 72 h. |
Rakshabhuva- nkar et al. [41] | N = 8 term and preterm | N = 5 HIE N = 2 IVH N = 1 N/A | N = 8 PHB (dose: N/A) N = N/A PHE (dose: N/A) | N = 8 LEV (10 mg/kg) | LEV’s effectiveness in 6/8 patients. |
Lo Yee Yau et al. [42] | N = 12 preterm and term | N = 6 HIE N = 3 CNS infections N = 1 hypoglicemia N = 2 metabolic | N = 12 PHB (dose: N/A) | N = 8 MDZ as 2nd line AED and LEV as 3rd line. N = 4 were given LEV as 2nd line AED. | LEV’s efficacy: 75% of patients treated. No side effects reported. |
Maljevic et al. [43] | N = 10 | KCNQ 3 mutations | N = 1 PYR N = 2 LEV N = 1 OXC | N = 1 LEV (65 mg/kg) N = 1 OXC (20 mg/kg) | 1 was seizure free after one dose of LEV. 1 was seizure free after day 20 on LEV. 1 was seizure free on OXC. |
Shin et al. [44] | N = 18 term and preterm | N = 12 HIE N = 1 CNS N = 1 IVH N = 4 malformative | N = 18 PHB or PHE (dose: N/A) | N = 18 LEV after PHB failure (N = 1 only LEV N = 11 LEV + PHB N = 6 PHE + LEV) | 94% of patients had seizure cessation within the first week from LEV’s introduction, and 89% remained seizure-free under LEV monotherapy at 1 month. |
Han et al. [45] | N = 37 preterm | N = 15 HIE N = 6 GMH N = 14 IVH N = 1 malformative N = 1 meningitis | LEV (40–60 mg/kg) | N = N/A PHB (20 mg/kg) N=N/A PHE, MDZ, TPM, VPA as 3rd line. | Seizure cessation in 21 patients (57%) with LEV alone. Seizure cessation in 9 infants (24%) after LEV + PHB. 7 required third-line AED. |
Venkatesan et al. [46] | N = 32 term | HIE | N = 23 PHB N = 2 LEV N = 2 MDZ (doses: N/A) | N = 23 LEV as 2nd line N = 2 LEV as 3rd line after PHB and MDZ failure | 84% of the patients treated with LEV achieved seizure cessation within 72 h. |
Rao et al. [47] | N = 44 term | HIE | N = 23 PHB N = 2 LEV | N = 10 LEV as 2nd line | 50% of patients treated with levetiracetam became seizure-free after 40 h, and 100% achieved seizure freedom between 100 and 120 h. |
Van der Broek et al. [48] | N = 31 term | HIE | N = 31 PHB (20 mg/kg) | / | PHB’s efficacy: 66%. |
Boylan et al. [49] | N = 14 term and preterm | N = 4 HIE N = 3 IVH N = 3 metabolic N = 1 meningitis N = 3 mild asphyxia | N = 14 PHB (20–40 mg/kg) | N = 4 CLZ N=N/A PHE (doses: N/A) | PHB was only effective in 29% of patients, those with normal background EEGs or mild to moderate background abnormalities and low seizure burden. |
Spagnoli et al. [50] | N = 91 term and preterm | N = 45 HIE N = 21 IVH N = 4 malformative N = 12 metabolic disorders N = 4 CNS infection N = 1 genetic N = 4 N/A | N = 91 PHB (20 mg/kg) | N = N/A PHE 20 mg/kg as 2nd line N = N/A MDZ 0.15 mg/kg as 3rd line | PHB was effective alone in 62.6% of patients. |
Hakeem et al. [51] | N = 11 term and preterm | N = 6 HIE N = 3 IVH N = 1 CNS N = 1 N/A | N = 2 oral cloral hydrate (30 mg/kg) N = 7 PHB (20 mg/kg) N = 2 DZP (1 to 2 mg iv bolus) | N = 1 CLZ c.i. (10 mcg/kg/hr) | 6/7 responded to PHB but 4/7 later relapsed. |
Weeke et al. [52] | N = 413 (N = 319 term, N = 94 preterm) | N = 228 HIE N = 45 HIE N = 32 PAIS N = 40 CNS infections N = 100 others | N = 413 PHB (dose: 20 mg/kg) | N = 186 LID as 2nd line N = 172 LID as 3rd line | In term infants, a response to LID was seen in 72.5–80%, with cessation of seizures and no need for rescue AED in 21.4–67.6%. Lower response rate in preterm (55.5–58.2% with cessation of seizures and no other AED in only 16.4–40.7%). |
Lundqvist et al. [53] | N = 30 term | N = 18 HIE N = 4 meningitis N = 6 PAIS N = 1 hypoglicemia N = 1 uncertain | N = 17 DZP (dose: N/A) N = 8 MDZ (dose: N/A) N = 5 DZP + MDZ (dose: N/A) | N = 30 LID | LID’s efficacy: 65%. |
Van der Broek et al. [54] | N = 22 term | HIE | N = 22 PHB (dose: N/A) | N = 22 MDZ (dose: N/A) N = 22 LID (dose: 2 mg/kg, followed by 4 mg/kg/h c.i.) | 20/22 (90%) newborns responded to LID. No cardiac arrythmias were reported (91%) |
Jennekens et al. [55] | N = 11 term | N = 11 stroke | N = 11 PHB (20 mg/kg) | N = 8 MDZ as 2nd line N = 9 LID as 3rd line | In term newborns with PAIS, MDZ and LID induce a shift from lower to higher frequency electrocortical activity. Compared to LID, MDZ reduced more pronouncedly the total EEG power. |
Shany et al. [56] | N = 30 term | N = 30 HIE | N = 30 DZP or PHB | N = 22 LID as 2nd line N = 8 MDZ as 2nd line | 77% response rate to LID. |
McDermott et al. [57] | N = 10 term | HIE | N = 5 LRZ N = 4 PHB or PHE (20 mg/kg) N = 1 PHB (20 mg/kg) | N = 5 LRZ as 2nd line | Administration of a single dose of LRZ stopped seizures in all neonates. 4 neonates receiving simultaneously PHB and/or PHE had no further seizures. 6 had seizure recurrence. |
Castro Conde et al. [58] | N = 13 term and preterm | N = 7 HIEN = 3 stroke N = 2 IVH N = 1 N/A | N = 32 PHB (20 mg/kg tritated up to 40 mg/kg) followed by PHE as 2nd line AED (20 mg/kg) | N = 13 MDZ as 2nd (9/13) or 3rd (4/13) line AED in non-responders. | Ten of 13 neonates with SE treated with midazolam were electrically controlled in the first hour of treatment. |
Vilan et al. [59] | N = 9 term | KCNQ2 mutations | N = 9 PHB | N = 8 PYR, N = 6 LID, N = 6 MDZ, N = 3 CZP, N = 3 LEV, N = 2 PHE, N = 2 VPA, N = 2 CBZ, N = 1 TPM | PH and PYR (used in 8/9 patients) were ineffective. 2 patients were SF during LID infusion and were later switched to oral PHT or oral CBZ. |
Montesclaros Hortigüela et al. [60] | N = 13 G.A. = N/A | KCNQ2 mutations | N = 10 PHB N = 2 LEV N = 1 MDZ (doses: N/A) | Several AED were administered as 2nd line: CBZ, LEV, MDZ, VPA, PHE, TPM, VGB, LID, OXC, PYR | 5/9 were seizure free but with severe impairment in psychomotor development in treatment with CBZ (n = 2), VPA + CBZ + LCM (n = 1), PHB + VPA + OXC (n = 1), OXC + TPM (n = 1). |
Pisano et al. [61] | N = 15 term | KCNQ2 mutations | Multiple AEDs (including PHB as first-line AED, VPA, steroids) were tried unsuccessfully | N = N/A CBZ (20 mg/kg/day) N = N/A PHE (dose widely ranging) | 53% of the patients were seizure-free on CBZ; 33% responded to PHE; the remaining 47% of the patients responded to TPM and LEV. |
Sands et al. [62] | N = 19 term | SLC13A5 mutations (KCNQ2 gene) | N = 13 PHB (dose: N/A) N = 4 CBZ (10 mg/kg) | N = 15 CBZ (10 mg/kg) | CBZ’s efficacy: 89%. |
Singh et al. [63] | N = 10 term | N = 8 HIE N = 2 unknown | N = 10 CBZ (dose: 10 mg/kg) | N = 2 DZP | Seizure control in 80% of patients on CBZ; 2 patients needed DZP as 2nd line. |
Glass et al. [64] | N = 6 term | HIE | N = 5 PHB (30–60 mg/kg) | N = 5 TPM (10 mg/kg) | 3/5 patients treated with TPM had seizure reduction or cessation. One adjunctive patient achieved seizure freedom on TPM at 6 months. |
Population | Etiology | Treatment | Add-on therapy | Outcome | |
---|---|---|---|---|---|
Shoemaker et al. [65] | N = 3 term and preterm | N = 1 PAIS N = 2 PHVD | N = 2 PHB and PHE (dose: N/A) N = 1 PHE and OXC (dose: N/A) | N = 3 LEV as 3rd line (dose: N/A) | LEV’s administration resulted in seizure control in all three patients. |
Tanriverdi et al. [66] | N = 1 term | SWS | PHB (20 mg/kg) | PHE as 2nd line (20 mg/kg) LEV as 3rd line (20 mg/kg) | Seizure control was achieved after LEV intravenous infusion. |
Hmaimess et al. [67] | N = 1 Term | KCNT1 mutation | PHB (dose: N/A) | PHT, LTG, CLZ LEV (10–30 mg/kg) | LEV’s introduction resulted in dramatic decrease in seizure activity by the eighth day of treatment. |
Ledet et al. [68] | N = 1 term | LLA | PHB (20 mg/kg) | LEV (40 mg/kg) | The patient was seizure-free on PHB and maintained seizure freedom on LEV that minimally interfered with her other ongoing treatments. |
Li Jiang et al. [69] | N = 9 term | STXBP1mutations | PHB (dose: N/A) | 5 patients did not respond and were tried on several AEDs (TPM, NZP, LEV, VPA, VIT B6, PDN, ACTH, KD) | 44.4% of cases (4/9) in our study showed apparent responses to LEV. |
Dilena et al. [70] | N = 1 term | SCN2A | PHB (dose: N/A) | LEV + PYR as 2nd line PHE as 3rd line (12–18 mg/kg/day) | Seizure freedom was reached on PHE, first, and maintained on oral CBZ. |
Bonhorst et al. [71] | N = 1 term | KCNQ2 | PHB (20 mg/kg) + VIT B6 (30 mg/kg/d) | MDZ c.i. as 2nd line (0.25 mg/kg/h) TPM as 3rd line (2 mg/kg/day) LID (6 mg/kg), then switched to PHE and, later CBZ (dose: N/A) | Seizure freedom was reached on LID; the patient developed methemoglobinemia as side-effect and seizure freedom was maintained with PHE, first, and oral CBZ, later. |
Numis et al. [72] | N = 3 term and late preterm | KCNQ2 encephalopathy | PHB (dose: N/A) | LEV, TPM, VGB, CLZ, KD failed. CBZ was initiated at 3, 4 and 13 months (dose: N/A) | 2/3 patients responded to CBZ and were seizure free at 30 months though developed severe psychomotor delay, quadriplegia, axial hypotonia with appendicular hypertonia, and a tendency to opisthotonos. |
Spagnoli et al. [73] | N = 1 term | EIMFS due to KCNQ2 mutations | PHB (dose N/A) | PYR, LEV, PHE, MDZ, TPM, NTZ CBZ (dose: N/A) | After multiple AEDs failure, seizure ceased after 3 weeks from CBZ’s introduction. Patient was seizure free at nine months. |
Blumkin et al. [74] | N = 1 Term | KNCQ2 | PHB (dose: N/A) | TPM, LEV, VPA, LTG, PYR, folinic acid CBZ (50 mg/kg) | Seizure control was initially achieved with TPM. Seizures reoccurred after 3 weeks and did not respond to several AEDs until CBZ. |
Buttle et al. [75] | N = 1 term | KCNQ2 | PHB (dose: N/A) | LEV, LRZ, CLZ, PYR LID (2–4 mg/kg/h) CBZ (40 mg/kg) | After several AEDs failed, seizure freedom was reached on LID and maintained at a 13 months follow-up on oral CBZ. |
Soldovieri et al. [76] | N = 1 term | KCNQ2 mutation (Kv7.2 subunit) | PHB (dose: N/A) | PYR, LEV, PHE, TPM, OXC | Partial response to an association of PHB, PHE, TPM. At 5 months he was switched to OXC and maintained seizure freedom until 14 months. The patient developed severe DD. |
McNally et al. [77] | N = 1 term | SCN8A | PHB (20 mg/kg) + LEV (20–60 mg/kg) | OXC (up to 80 mg/kg) + PHE (20 mg/kg) + LTG (2 mg/kg/day) | The association of three sodium channel blockers (OXC + PHE + LTG) reduced seizures’ frequency. |
Okumura et al. [78] | N = 1 term | 2q21-q31deletion (SCN1A cluster) | PHB (dose: 20 mg/kg) | LEV as 2nd line (40 mg/kg) VPA as 3rd line (50 mg/kg) | PHB and LEV failed to control seizures; VPA reduced seizures’ frequency. |
Riesgo et al. [79] | N = 3 preterm and term | N = 1 NAS N = 1 fetal distress N = 1 PVL | PHB (dose: N/A) | TPM (0.5–8 mg/kg/d) after several other AEDs failed (PHB, PHE, CLZ, VPA, MDZ) | Seizure cessation in all three after TPM’s administration. |
Sirsi et al. [80] | N = 3 term | N = 1 HIE N = 1 meningitis N = 1 EIEE | PHB (dose: N/A) | PHE as 2nd line (dose: N/A) MDZ as 3rd line (up to 0.2 mcg/kg/h) | Seizure control within 6–72 h after MDZ’s introduction. One patient developed hypotension, that responded to inotropic support. |
Steinberg et al. [81] | N = 2 preterm | N = 1 IVHN = 1 PVL | PHB (20 mg/kg) | PHE as 2nd line (20 mg/kg) Rectal VPA as 3rd line (20–30 mg/kg) | Seizure control was achieved and maintained on a 12 months follow-up on VPA. |
Tarocco et al. [82] | N = 1 late preterm | Pierre-Robin, polymicrogyria, lissencephaly | PHB (dose: N/A) | PHE, MDZ, LEV, PPF KTM (2 mg/kg + c.i. of 10 mcg/kg/min) | Immediate complete clinical and electrographic response was obtained after KTM introduction; after 15 days SE relapsed and the patient died. |
Baxter et al. [83] | N = 3 term | N = 2 EIEE N = 1 Aicardi-Goutieres | PHB (dose: N/A) | PYR, CLZ, VPA VGB (40 mg/kg/d) | 2/3 patients showed full response to VGB. |
Wolf et al. [84] | N = 1 term | Incontinentia pigmenti | PHB (35 mg/kg) | LRZ as 2nd line (0.2 mg/kg) PHE as 3rd line (20 mg/kg) Dexamethasone (0.25 mg/kg/d) | Rapid improvement and clinical seizures termination followed the initiation of CCS therapy. |
Shevell et al. [85] | N = 1 term | BFNE | PHB (10 mg/kg) | / | Patient presented no more seizures, was discharged home on oral PHB, suspended at five months of life |
Lee et al. [86] | N = 1 term | KCNQ2 | PHB (6 mg/kg/day) | PHE as 2nd line (8 mg/kg/day) VGB (50 mg/kg/day) | VGB reduced seizures; Once treatment with Vigabatrin was administered seizures reduced to one per day until day 24 of post-natal life, time at which the last seizure was recorded. |
Sato et al. [87] | N = 2 late preterm and term | HIE | PHB (10 mg/kg) | / | Both patients temporarily controlled seizures on PHB. One relapsed and developed severe DD. |
Sillanpää et al. [88] | N = 1 term | Feeding epilepsy | PHB (60 mg/day) + chlorpromazine (9 mg/day) | The patient was seizure-free since day 14 of PHB. | Only few cases of neonatal feeding seizures are described. In this case the patient was seizure-free on PHB, after a six days combination-therapy with chlorpromazine. |
Tramonte et al. [89] | N = 1 term | Temporal lobe hemorrhage | PHB (dose: N/A) | / | After PHB’s administration no more autonomic seizures (apnea, desaturations) were noticed. |
Future directions
Results
Limitations
Hypoxic-ischemic encephalopathy
N of patients treated | N of patients treated as 1st-line | Efficacy as 1st-line AED; N (%) | N of patients treated as 2nd-line | Efficacy as 2nd-line; N (%) | N of patients treated as 3rd-line | Efficacy as 3rd-line; N (%) | Overall efficacy | Side-effects | |
---|---|---|---|---|---|---|---|---|---|
Phenobarbital | 76 | 76 | 49 (65%) | / | / | / | / | 65% | None reported |
Lorazepam | 10 | 5 | 2 (20%) | 5 | 2 (20%) | / | 4 (40%) | Liver enzyme elevation in 1 patient | |
Midazolam | 333 | / | / | 226 | 14–50% | 107 | 57.5% | 36% | Hypotension in 39 patients (12%) |
Lidocaine | 317 | / | / | 208 | 94 (45%) | 125 | 91 (73.4%) | 59% | None reported |
Levetiracetam | 76 | 22 | Seizure freedom in 11 (50%) patients after 40 h, in 22 (100%) after 5 days | 54 | 49 (92%) | / | / | 75% | None reported |
Bumetanide | 14 | 14 | 7 (50%) | / | / | / | / | N/A | Ototoxicity |
Stroke
Population | First-line AED | Response to first-line AED | Response to Lidocaine as a 2nd−/3rd-line AED | Response to Midazolam as a 2nd−/3rd-line AED | Response to other AEDs |
---|---|---|---|---|---|
45 newborns with stroke | 45 (100%) phenobarbital | 4 (5%) did not require further treatment | 27 out of 32 (84%) patients treated with lidocaine responded (higher in full-term newborns and when used as a 2nd-line AED) | 5 out of 32 (16%) patients treated with midazolam responded | 1 patient responded to levetiracetam as a 3rd-line AED |
Genetic Channelopathies
N of patients | Gene mutation | Response to carbamazepine N (%) | Response to lidocaine N (%) | Response to phenytoin N (%) | Response to other AEDS N (%) | Maintenance | Side effects | Follow-up |
---|---|---|---|---|---|---|---|---|
66 | KCNQ2 | 40 (61%) Carbamazepine | 4 (6%) lidocaine | 7 (10%) phenytoin | 13 (20%) combination of drugs, including Na-channel blockers | 44 (66%) carbamazepine | 1 methemoglobinemia (on lidocaine) | Follow-up: from 3 months to 10 years. Normal development for BFNE; severe developmental delay in KCNQ2 encephalopathy |
6 | KCNQ3 | 1 (16%) oxcarbazepine (20 mg/kg) | / | / | 2 (33%) levetiracetam (70–85 mg/kg) | 1 (16%) oxcarbazepine 2 (33%) levetiracetam | None reported | Normal up to 4 years |
1 | KCNT1 | / | / | 0 (0%) | No response to phenobarbital, lamotrigine, or benzodiazepines. 1 (100%) levetiracetam 10–30 mg/kg | levetiracetam 30 mg/kg/day | None reported | Seizure decrease (still 1 episode/day) at 14 months |
1 | SCN2A | / | / | 1 (100%) phenytoin 20 mg/kg | / | carbamazepine 30 mg/kg | None reported | Severe developmental delay at 2 years |
1 | SCN1A | / | / | / | 1 (100%) valproate 50 mg/kg | valproate 50 mg/kg | N/A | Severe developmental delay at 3 years |
1 | SCN8A | 0 (0%) oxcarbazepine 80 mg/kg | 0 (0%) phenytoin 20 mg/kg | Seizure reduction on a combination of oxcarbazepine, phenytoin, and lamotrigine | phenytoin, oxcarbazepine, phenobarbital, lamotrigine | N/A | Daily seizures at 6 months |